1. Cytomegalovirus events in high‐risk allogeneic hematopoietic‐cell transplantation patients who received letermovir prophylaxis. Issue 4 (5th May 2021) Authors: Chen, Kaiwen; Arbona‐Haddad, Esther; Cheng, Matthew P.; McDonnell, Anne M.; Gooptu, Mahasweta; Orejas, Jose L.; Timblin, Kaitlyn; Silverman, Emily; Al‐Hamed, Rama; Soiffer, Robert J.; Hammond, Sarah P.; Marty, Francisco M. Journal: Transplant infectious disease Issue: Volume 23:Issue 4(2021) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes. Issue 34 (1st December 2022) Authors: Mishra, Asmita; Tamari, Roni; DeZern, Amy E.; Byrne, Michael T.; Gooptu, Mahasweta; Chen, Yi-Bin; Deeg, H. Joachim; Sallman, David; Gallacher, Phillip; Wennborg, Anders; Hickman, Denice K.; Attar, Eyal C.; Fernandez, Hugo F. Journal: Journal of clinical oncology Issue: Volume 40:Issue 34(2022) Page Start: 3985 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗